Scholarlink

Background <p>The study aims to explore the value of the six-minute walk test (6MWT) in assessing the severity and prognosis of patients with lymphangioleiomyomatosis (LAM).</p> Methods <p>A retrospective analysis was conducted on 403 LAM patients from the LAM registry study at the Peking Union Medical College Hospital (PUMCH). Survival and progression datasets were constructed. Results: ROC curve analysis established the optimal cut-off value for the six-minute walk distance (6MWD) to predict increased risk of mortality was 425.5&#xa0;m. The 6MWD low group (6MWD &lt; 425.5&#xa0;m) exhibited lower SpO₂, higher rates of desaturation, higher post-6MWT Borg dyspnea scale scores, worse pulmonary function indicators (FEV<sub>1</sub>%pred and DLCO%pred), and poorer quality of life assessments (SGRQ) (<i>P</i> &lt; 0.001). Furthermore, the 6MWD showed a significant positive correlation with baseline FEV<sub>1</sub>%pred (<i>P</i> &lt; 0.001). Multivariate regression analysis indicated that 6MWD, age, desaturation, and post-6MWT Borg dyspnea scale scores were independently correlated with baseline FEV<sub>1</sub>%pred (<i>P</i> &lt; 0.001). Progression dataset analysis demonstrated no significant correlation between 6MWT parameters and the annual decline in FEV<sub>1</sub>. Kaplan-Meier survival curves showed a significantly reduced survival probability for patients with 6MWD &lt; 425.5&#xa0;m, desaturation, or post-6MWT Borg dyspnea scale≥2. Multivariate Cox regression indicated that 6MWD &lt; 425.5&#xa0;m (HR = 3.759, <i>P</i> = 0.0375), FEV<sub>1</sub>%pred &lt; 70% (HR = 12.48, <i>P</i> = 0.0045), and sirolimus (HR = 0.1194, <i>P</i> &lt; 0.001) were independent factors affecting survival in patients.</p> Conclusions <p>6-minute walk distance effectively reflects the physical condition and prognosis and can be utilized as an important tool for clinical assessment in LAM patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Six-minute walk distance predicting the risk of mortality in lymphangioleiomyomatosis patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月10日

查看全文
  • Luning Yang,
  • Xiaoxin Zhang,
  • Luyi Wang,
  • Chongsheng Cheng,
  • Hanghang Wang,
  • Miaoyan Zhang,
  • Song Liu,
  • Wenshuai Xu,
  • Junya Liu,
  • Jinrong Dai,
  • Shuzhen Meng,
  • Yanli Yang,
  • Shao-Ting Wang,
  • Xinlun Tian,
  • Kai-Feng Xu

摘要

Background

The study aims to explore the value of the six-minute walk test (6MWT) in assessing the severity and prognosis of patients with lymphangioleiomyomatosis (LAM).

Methods

A retrospective analysis was conducted on 403 LAM patients from the LAM registry study at the Peking Union Medical College Hospital (PUMCH). Survival and progression datasets were constructed. Results: ROC curve analysis established the optimal cut-off value for the six-minute walk distance (6MWD) to predict increased risk of mortality was 425.5 m. The 6MWD low group (6MWD < 425.5 m) exhibited lower SpO₂, higher rates of desaturation, higher post-6MWT Borg dyspnea scale scores, worse pulmonary function indicators (FEV1%pred and DLCO%pred), and poorer quality of life assessments (SGRQ) (P < 0.001). Furthermore, the 6MWD showed a significant positive correlation with baseline FEV1%pred (P < 0.001). Multivariate regression analysis indicated that 6MWD, age, desaturation, and post-6MWT Borg dyspnea scale scores were independently correlated with baseline FEV1%pred (P < 0.001). Progression dataset analysis demonstrated no significant correlation between 6MWT parameters and the annual decline in FEV1. Kaplan-Meier survival curves showed a significantly reduced survival probability for patients with 6MWD < 425.5 m, desaturation, or post-6MWT Borg dyspnea scale≥2. Multivariate Cox regression indicated that 6MWD < 425.5 m (HR = 3.759, P = 0.0375), FEV1%pred < 70% (HR = 12.48, P = 0.0045), and sirolimus (HR = 0.1194, P < 0.001) were independent factors affecting survival in patients.

Conclusions

6-minute walk distance effectively reflects the physical condition and prognosis and can be utilized as an important tool for clinical assessment in LAM patients.